Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy
Tumor hypersialylation drives immunosuppression and limits immunotherapy efficacy by shielding tumor cells and engaging inhibitory immune receptors. Here, we engineered Escherichia coli Nissle 1917 (EcNΔpgi-SAS) as a metabolically confined “desialylation catalyst” to remodel the tumor microenvironment. This strain comb...